Close Menu

NEW YORK (GenomeWeb) – Cepheid announced today that it has received 510(k) clearance and CLIA waiver from the US Food and Drug Administration for a new test system and influenza molecular diagnostic test.

The test, called Xpert Xpress Flu, can be used in near-patient settings to detect both A and B strains of influenza from either nasopharyngeal or nasal swabs. It targets multiple regions within the RNA-based influenza genomes to increase sensitivity and guard against antigenic drift.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
24
Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.